Synergy of HLA class I and II shapes the timing of antitumor immune response
B. T. Papp, A. T. Fulop, G. M. Balogh, B. Koncz, D. Spekhardt, M. Manczinger
The paper examines how combinations of HLA class I and II variants affect antitumor immune response timing and patient survival in melanoma.
bioRxiv · Nov 16, 2022 · PreprintCancer Biology